These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27853282)

  • 1. Novel Podophyllotoxin Derivatives as Partial PPARγ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes.
    Zhang X; Liu H; Sun B; Sun Y; Zhong W; Liu Y; Chen S; Ling H; Zhou L; Jing X; Qin Y; Xiao T; Sun T; Zhou H; Yang C
    Sci Rep; 2016 Nov; 6():37323. PubMed ID: 27853282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor γ with Excellent Effect on Insulin Resistance and Type 2 Diabetes.
    Liu HJ; Zhang CY; Song F; Xiao T; Meng J; Zhang Q; Liang CL; Li S; Wang J; Zhang B; Liu YR; Sun T; Zhou HG
    J Pharmacol Exp Ther; 2015 Jun; 353(3):573-81. PubMed ID: 25876909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes.
    Yasmin S; Capone F; Laghezza A; Piaz FD; Loiodice F; Vijayan V; Devadasan V; Mondal SK; Atlı Ö; Baysal M; Pattnaik AK; Jayaprakash V; Lavecchia A
    Sci Rep; 2017 Oct; 7(1):14453. PubMed ID: 29089569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gallic acid attenuates high-fat diet fed-streptozotocin-induced insulin resistance via partial agonism of PPARγ in experimental type 2 diabetic rats and enhances glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway.
    Gandhi GR; Jothi G; Antony PJ; Balakrishna K; Paulraj MG; Ignacimuthu S; Stalin A; Al-Dhabi NA
    Eur J Pharmacol; 2014 Dec; 745():201-16. PubMed ID: 25445038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
    Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
    J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin sensitization via partial agonism of PPARγ and glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway by embelin in type 2 diabetic rats.
    Gandhi GR; Stalin A; Balakrishna K; Ignacimuthu S; Paulraj MG; Vishal R
    Biochim Biophys Acta; 2013 Jan; 1830(1):2243-55. PubMed ID: 23104384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (S)-1,2,3,4-Tetrahydroisoquinoline Derivatives Substituted with an Acidic Group at the 6-Position as a Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonist.
    Morishita K; Miike T; Takeda S; Fukui M; Ito Y; Kitao T; Ozawa SI; Hirono S; Shirahase H
    Chem Pharm Bull (Tokyo); 2019; 67(11):1211-1224. PubMed ID: 31685749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of KY-903, a Novel Tetrazole-Based Peroxisome Proliferator-Activated Receptor γ Modulator, in Male Diabetic Mice and Female Ovariectomized Rats.
    Ito Y; Yamamoto M; Furukawa S; Fukui M; Morishita K; Kitao T; Shirahase H
    Biol Pharm Bull; 2021; 44(5):659-668. PubMed ID: 33952822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L; Bahij El-Houri R
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism.
    Kim SH; Hong SH; Park YJ; Sung JH; Suh W; Lee KW; Jung K; Lim C; Kim JH; Kim H; Park KS; Park SG
    Sci Rep; 2019 Feb; 9(1):1656. PubMed ID: 30733541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel PPARα/γ agonist, propane-2-sulfonic acid octadec-9-enyl-amide, ameliorates insulin resistance and gluconeogenesis in vivo and vitro.
    Ren T; Yang WS; Lin Y; Liu JF; Li Y; Yang LC; Zeng KY; Peng L; Liu YJ; Ye ZH; Luo XM; Ke YJ; Diao Y; Jin X
    Eur J Pharmacol; 2018 May; 826():1-8. PubMed ID: 29476879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
    Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
    Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus.
    Tabassum A; Mahboob T
    Hum Exp Toxicol; 2018 Nov; 37(11):1187-1198. PubMed ID: 29441829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
    Ibrahim MK; Eissa IH; Alesawy MS; Metwaly AM; Radwan MM; ElSohly MA
    Bioorg Med Chem; 2017 Sep; 25(17):4723-4744. PubMed ID: 28720328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
    Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
    Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus.
    Jiang LY; Tang SS; Wang XY; Liu LP; Long Y; Hu M; Liao MX; Ding QL; Hu W; Li JC; Hong H
    CNS Neurosci Ther; 2012 Aug; 18(8):659-66. PubMed ID: 22620268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ankaflavin: a natural novel PPARγ agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo.
    Lee BH; Hsu WH; Chang YY; Kuo HF; Hsu YW; Pan TM
    Free Radic Biol Med; 2012 Dec; 53(11):2008-16. PubMed ID: 23022408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
    Gaikwad AB; Viswanad B; Ramarao P
    Pharmacol Res; 2007 May; 55(5):400-7. PubMed ID: 17369046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice.
    Huan Y; Pan X; Peng J; Jia C; Sun S; Bai G; Wang X; Zhou T; Li R; Liu S; Li C; Liu Q; Liu Z; Shen Z
    Diabetes Obes Metab; 2019 Nov; 21(11):2553-2563. PubMed ID: 31364797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.